Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Mavrostobart (PT199)
Mavrostobart · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A: Monotherapy Dose Escalation | EXPERIMENTAL | A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. Mavrostobart (PT199) will be administered as a monotherapy. |
| Part B: Combination Therapy Dose Escalation | EXPERIMENTAL | A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. Patients will be treated with Mavrostobart (PT199) in combination with a PD-1 inhibitor, tislelizumab. |
| Part C: Combination Therapy Dose Expansion | EXPERIMENTAL | Two RDEs for Part C will be determined in Part B and will be further evaluated in two dose expansion cohorts. Patients will be treated with Mavrostobart (PT199) in combination with a PD-1 inhibitor, tislelizumab. |
| Part D: Chemotherapy Combination | EXPERIMENTAL | The Chemotherapy Combination Therapy Dose Escalation and Expansion will investigate four cohorts, one in frontline PDAC, two in frontline NSCLC and one in second-line and later NSCLC patients. Patients will receive Mavrostobart (PT199) plus chemotherapy, with one cohort also receiving pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| Mavrostobart (PT199) | DRUG | Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action. |
| Tislelizumab | DRUG | Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response. |
| Gemcitabine + nab-Paclitaxel | DRUG | Dosing is per Standard of Care. |
| Docetaxel | DRUG | Dosing is per Standard of Care. |
| Pemetrexed | DRUG | Dosing is per Standard of Care. |
| Gemcitabine | DRUG | Dosing is per Standard of Care. |
| Carboplatin + Pemetrexed | DRUG | Dosing is per Standard of Care. |
| Pembrolizumab + Carboplatin + Pemetrexed | DRUG | Dosing is per Standard of Care. |
Key Inclusion Criteria 1. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors. 2. For Part A: a histologically or cytologically confirmed unresectable advanced or metastatic solid tumors previously treated with therapies, or for which treatment is not available or not...
Top 20 of 84 competitors
Mavrostobart is an investigational small molecule being developed for the treatment of Non Small Cell Lung Cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with this type of cancer to evaluate its safety and efficacy.
Mavrostobart is an anti-CD73 monoclonal antibody that targets the CD73 protein. By targeting CD73, the drug aims to modulate the tumor microenvironment and enhance the body's immune response against cancer cells. This mechanism is being investigated in the context of Non Small Cell Lung Cancer treatment.
Mavrostobart is being developed by BeOne Medicines Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol ONC. The company is conducting clinical trials to evaluate the drug's potential as a treatment for Non Small Cell Lung Cancer.
Mavrostobart is currently in Phase 1 clinical development. It is an investigational drug that has not yet received regulatory approval. The Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in patients with Non Small Cell Lung Cancer.
Mavrostobart is being studied in a Phase 1 clinical trial with the identifier NCT05431270. This trial is a dose escalation and expansion study that evaluates Mavrostobart administered alone and in combination with a PD-1 inhibitor or chemotherapy. The study is recruiting patients with Non Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma in the United States.
Yes, Mavrostobart is also known as PT199. The drug is referred to by both names in clinical and research contexts. This alternative name is used in the clinical trial NCT05431270, which is investigating the drug for the treatment of Non Small Cell Lung Cancer.